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The initiation of cytotoxic immune responses by den-
dritic cells (DCs) requires the presentation of anti-
genic peptides derived fromphagocytosedmicrobes
and infected or dead cells to CD8+ T cells, a process
called cross-presentation. Antigen cross-presenta-
tion by non-activated DCs, however, is not sufficient
for the effective induction of immune responses.
Additionally, DCs need to be activated through
innate receptors, like Toll-like receptors (TLRs). Dur-
ing DC maturation, cross-presentation efficiency is
first upregulated and then turned off. Here we show
that during this transient phase of enhanced cross-
presentation, phago-lysosome fusion was blocked
by the topological re-organization of lysosomes
into perinuclear clusters. LPS-induced lysosomal
clustering, inhibition of phago-lysosome fusion and
enhanced cross-presentation, all required expres-
sion of the GTPase Rab34. We conclude that TLR4
engagement induces a Rab34-dependent re-organi-
zation of lysosomal distribution that delays antigen
degradation to transiently enhance cross-presenta-
tion, thereby optimizing the priming of CD8+ T cell re-
sponses against pathogens.
INTRODUCTION
Phagocytosis represents a critical innate barrier against infection
and serves the clearance of extracellular microbes, infected and
non-infected cells. After uptake, phagosomes undergo sequen-Immtial fusion and fission events, first with endosomal and then
lysosomal compartments leading to degradation of the phago-
some content, a process referred to as ‘‘phagosome matura-
tion’’ (Flannagan et al., 2009). Phagosome maturation includes
the acquisition of hydrolases, NADPH oxidases, and vacuolar
ATPases (Kinchen and Ravichandran, 2008). Mature phago-
lysosomes display effective anti-microbial capacity.
In contrast to macrophages or neutrophils, which use phago-
cytosis for microbe destruction, phagocytosis in dendritic cells
(DCs) mainly serves antigen processing and presentation (Sa-
vina and Amigorena, 2007). Major histocompatibility complex
(MHC) class I presentation is classically restricted to endoge-
nous antigens. However, also exogenous antigens can be pre-
sented on MHC I molecules in a process called cross-presenta-
tion, which is required for the initiation of cytotoxic immune
responses against bacteria, tumors, certain viruses, and for the
maintenance of self tolerance (Joffre et al., 2012). DCs have
developed a specialized phagocytic pathway, which allows
optimal conditions for cross-presentation (Savina and Amigor-
ena, 2007). These specializations include a mildly degradative
phagosomal environment, export of antigen to the cytosol for
proteasome-mediated degradation, and effective loading of
the generated peptides in the endoplasmic reticulum (ER) or in
phagosomes (Guermonprez et al., 2003). Indeed, slow matura-
tion and acidification of phagosomes (Savina et al., 2006,
2009), as well as limited degradation (Gil-Torregrosa et al.,
2004; Lennon-Dume´nil et al., 2002; Inaba et al., 2000) are critical
for cross-presentation.
Another direct consequence of phagosome specialization
is the discrimination of self from non-self phagosomal cargo
through engagement of pattern-recognition receptors. Cargoes
that engage Toll-like receptors (TLRs) accelerate phagosome
maturation in the first few hours after uptake. This effect is phag-
osome autonomous, as TLR engagement in one phagosomeunity 43, 1087–1100, December 15, 2015 ª2015 Elsevier Inc. 1087
does not affect the maturation of other phagosomes containing
cargoes that do not engage TLRs (Blander and Medzhitov,
2006). By controlling phagosome maturation, TLR engagement
promotes antigen presentation on both MHC I and II molecules.
The mechanisms underlying the effects of TLR engagement on
antigen presentation are, however, incompletely understood.
Recently, the Blander laboratory has shown that TLR engage-
ment during uptake of phagosomal cargo induces SNAP23-
dependent recruitment of MHC I molecules from endosomal
recycling compartments, thereby promoting cross-presentation
in the first few hours after uptake (Nair-Gupta et al., 2014).
TLR engagement also initiates a complex gene expression
program that transforms immature DCs into full effectors
of immunity. DC maturation includes profound changes in
morphology, cytoskeleton organization, and protein expression,
either at the cell surface or as secreted mediators (Pierre et al.,
1997; Reis e Sousa, 2006; Stuart and Ezekowitz, 2005). DCs
lose their phagocytic capacity as theymature in response to lipo-
polysaccharide (LPS) both in vitro (Sallusto and Lanzavecchia,
1994; West et al., 2004), and in vivo (Wilson et al., 2006). Recent
studies, however, showed that endocytosis and phagocytosis
are actually only slowed down, and are even unaffected when
mediated through certain phagocytic receptors, such as Fcg
receptors (Platt et al., 2010). Mature DCs also acidify their endo-
cytic compartments more efficiently than immature DCs (Sepul-
veda et al., 2009; Trombetta et al., 2003). The ability of DCs to
cross-present antigens is transiently enhanced in the first 20 hr
after TLR stimulation and then down-modulated after 24–40 hr
(Gil-Torregrosa et al., 2004). This can be physiologically relevant
to enable activated DCs to enter a ‘‘surveillance’’ state that
allows internalization of additional antigen before inducing effec-
tive T cell priming.
Here, we analyze how enhanced cross-presentation induced
by LPS is determined by changes in phagocytic functions during
the intermediate phases of DC maturation. We show that LPS
induced a strong and selective delay in the fusion activity be-
tween phagosomes and lysosomes. This delay prevented
excessive degradation of internalized antigen and promoted
cross-presentation. Delayed phago-lysosome fusion in LPS-
treated cells required Rab34-mediated re-distribution of lyso-
somes into a dense perinuclear cluster, and slowed down dis-
placements of phagosomes along microtubules. These results
describe a mechanism of inhibition of phago-lysosome fusion
that functionally links innate pathogen sensing in DCs and anti-
gen cross-presentation.
RESULTS
Maturing DCs Capture and Cross-Present Antigen to
T Cells More Efficiently Than Resting Cells In Vitro or
In Vivo
We have shown previously that 24–40 hr after activation by LPS,
the efficiency of cross-presentation of antigen-immunoglobulin
G immune complexes (ICs) is downregulated in vitro (Gil-Torre-
grosa et al., 2004), as also reported by others using other forms
of antigen both in vitro and in vivo (Wilson et al., 2006; Wagner
and Cresswell, 2012; Samie and Cresswell, 2015). Nevertheless,
before this reduction in cross-presentation, DCs go through a
transient phase of increased efficiency of cross-presentation1088 Immunity 43, 1087–1100, December 15, 2015 ª2015 Elsevier In(Gil-Torregrosa et al., 2004). To further investigate the duration
of this transient phase, which was initially tested after 5 hr
of LPS, we examined later time points of 16 and 24 hr of LPS
stimulation, when the expression of co-stimulatory molecules
and MHC II molecules on the DC surface was already high (Fig-
ure S1A and B). The octapeptide SIINFEKL (OVA amino acids
257–264), which is recognized by both B3Z (a Kb-restricted,
OVA-specific CD8+ T cell hybridoma) and OT-I (TCR trans-
genic Kb OVA-specific CD8+ T lymphocytes, Kurts et al., 1996)
T cells and does not need processing or proteasomal degrada-
tion, was presented with equal efficiency by LPS-treated and
resting bone-marrow-derived DCs (BMDCs) (Figure 1A and
S1C right panel). In contrast, cross-presentation of both bead-
bound OVA (bbOVA, Figure 1B) and soluble OVA (sOVA, Fig-
ure 1C), to either OT-I or B3Z T cells, was increased in cells
treated with LPS for 16 hr, as compared to resting BMDCs. After
24 hr, as shown previously (Gil-Torregrosa et al., 2004; Wagner
and Cresswell, 2012), the efficiency of cross-presentation was
reduced, as compared to both untreated, and cells treated
with LPS for 16 hr (Figure S1C). Therefore, LPS induces a pro-
longed (up to 16 hr) phase of enhanced cross-presentation in
maturing DCs, before it is down-modulated after 24 hr of stimu-
lation (Figure S1C).
To investigate whether this prolonged phase of increased
cross-presentation is also observed during activation of DCs
in vivo, we gave mice LPS intraperitoneally followed by intrave-
nous injection of bbOVA (14 hr later), sOVA, or OVA-IC (15.5 hr
later) (Figure 1D). 16 hr after LPS injection, total splenic
CD11c+ cells (for sOVA or OVA-ICs) or CD8+ T cells having
phagocytosed beads (for bbOVA) were sorted (Figure S1G)
and co-cultured with OT-I T cells to measure antigen-specific
T cell activation. Sixteen hr after injection of LPS, CD11c+ splenic
DCs expressed increased amounts of co-stimulatory molecules,
as compared to cells from mice injected with PBS (Figure S1D).
Of note, the percentage of phagocytic DCs was reduced in LPS-
treated mice, but the relative number of cells having phagocy-
tosed 1 or 2 beads was the same (Figure S1G). As shown in
Figures 1E and 1J, splenic DCs from LPS-treated mice cross-
presented bbOVA (Figures 1E and 1F), sOVA (Figures 1G and
1H) andOVA-IC (Figures 1I and 1J) to OT-I T cells more efficiently
than untreated mice (as assessed by increased expression of
CD25 and CD69 in OT-I T cells). We conclude that DCs activated
in vivo during 16 hr by LPS cross-present antigen more effec-
tively than resting DCs.
LPS Induces a TLR4-Dependent Decrease in
Degradation of Phagosomal Antigen and
Phago-Lysosomal Fusion
To explore the mechanism underlying this temporary increase
in cross-presentation, we first tested whether it is due to
augmented antigen uptake (a transient, but very short increase
in macropinocytosis was described previously, West et al.,
2004). BMDCs treated with LPS for 16 hr still internalized bbOVA,
but at lower rates than resting BMDCs (Figures S1H and S1I).
Therefore, increased cross-presentation in LPS-treated cells
cannot be explained by higher antigen uptake. To test other
forms of phagocytic cargo, we analyzed the uptake of OVA-ex-
pressing E. coli and of ultraviolet C-irradiated H2bm1 transformed
mouse embryonic fibroblasts (dead cell-OVA). Phagocytosis ofc.
Figure 1. DC Matured In Vivo or In Vitro Are
Able to Capture and Cross-Present Antigen
More Efficiently Compared to Resting Cells
(A–C) BMDCs were incubated for 16 hr in presence
(filled circles) or absence of 100 ng/ml LPS (open
squares) before SIINFEKL peptide (A), bbOVA (B)
and sOVA (C) were added. Cross-presentation
efficiency of DCs wasmeasured by co-culture with
B3Z cells (left panel), CD69 expression of OT-I
T cells (middle panel), and proliferation of CFSE-
labeled OT-I T cells (right panel) (upper, middle,
and lower panels, respectively, for Figure 1A).
Shown is one representative out of three inde-
pendent experiments.
(D) Experimental scheme for in vivo cross-
presentation assays. OT-I T cell activation was
measured by CD25 and CD69 expression, after
co-culture for 16 hr with splenic DCs from mice
non-treated (left panels) and systemically treated
with LPS (right panels), immunized with bbOVA (E),
sOVA (G), and OVA-IC (I).
(F, H, and J) Histograms display the average of
three independent experiments for each of the
mentioned antigens. Error bars represent SD. See
also Figures S1 and S2.E. coli, alive (Figure S2A), paraformaldehyde-fixed (Figure S2B),
heat-killed (Figure S2C), and dead cell-OVA (Figure S2D) was
observed in both resting and 16 hr LPS-activated BMDCs,
always with lower efficiencies in LPS-treated cells.
We then investigated whether the transient increase in cross-
presentation could be attributed to a temporary increase in anti-
gen export to the cytosol using a previously described assay
based on the enzymatic activity of b-lactamase (Cebrian et al.,Immunity 43, 1087–1100, De2011). As shown in Figure S1J, after
16 hr of LPS treatment, antigen export
to the cytosol was not significantly modi-
fied, as compared to resting BMDCs.
Therefore, LPS-treated DCs cross-pre-
sent phagosomal and endosomal anti-
gens more efficiently than resting DCs, a
difference that is not due to increased up-
take or to changes in antigen export to the
cytosol.
To further investigate how DC matura-
tion favors cross-presentation, we char-
acterized the degradative capacity of
phagosomes and fusion with lysosomes
in resting and 16 hr LPS-treated BMDCs,
using bbOVA and single organelle-based
flow cytometry (Savina et al., 2010). This
technique allows simultaneous analysis
of OVA degradation and acquisition of
lysosomal markers (e.g., LAMP-1) exclu-
sively in phagocytosed beads. In resting
BMDCs, the proportion of beads bearing
low amounts of OVA (due to degradation)
and high amounts of LAMP-1 (due to
phagosome maturation into phago-lyso-
somes) increased over time (Figure 2A).Similar results were found when lysosomes were pre-loaded
with fluorescently labeled wheat germ agglutinin (WGA) before
bead internalization (Figures S3A–S3D), indicating effective
fusion between phagosomes and lysosomes. In 16 hr LPS-
treated cells (100 ng/ml, Figure 2A or 10 ng/ml, Figures S3E
and S3F), very few phagosomes with low OVA amounts and
high LAMP-1 amounts appeared over time, indicating reduced
degradation of OVA and delayed phagosome fusion withcember 15, 2015 ª2015 Elsevier Inc. 1089
Figure 2. Activation of TLR4 by LPS Leads to Delayed Phagosomal
Antigen Degradation
DCs were incubated for 16 hr in presence or absence of 100 ng/ml LPS before
bbOVA was phagocytosed. Phagosome maturation was analyzed by flow
organellocytometry in WT BMDCs (A), TLR4-deficient BMDCs (B), and splenic
DCs (C). Histograms depict phagosomal OVA degradation (left panel) as well
as phagosomal acquisition of LAMP-1 (right panel) after different chase
periods. The data displayed here is a representative example of three inde-
pendent experiments. See also Figures S1, S3, and S5.
1090 Immunity 43, 1087–1100, December 15, 2015 ª2015 Elsevier Inlysosomes. Similarly, the proportion of WGA-positive phago-
somes was very low in LPS-treated BMDCs, as compared to
resting cells (Figure S3B). Reduced phago-lysosome fusion
was also observed after 12 hr, but not after 6 hr, of LPS stimula-
tion (Figures S3G and S3H). In addition, a similar reduction in
phagosomal OVA and LAMP-1 proportions was observed after
treating splenic DCs with LPS (Figure 2C and S1F). Reduced
phago-lysosomal fusion was not observed when BMDCs lacked
expression of TLR4 (Figure 2B), which as expected did not
mature in response to LPS (Figure S1E). We conclude that
16 hr after engagement of TLR4, a substantial proportion (up
to 50%) of phagosomes, in both BMDCs and splenic DCs, fail
to effectively degrade OVA or to fuse with lysosomes.
Phagosomes of Resting DCs Are Highly Enriched in
Lysosomal Enzymes
Reduced OVA degradation and increased acquisition of LAMP-1
orWGA in phagosomes suggest reduced fusion with lysosomes.
In order to perform amore detailed analysis of the composition of
phagosomes in resting and LPS-treated BMDCs, phagosomes
were purified, and their proteome was analyzed using a quanti-
tative shotgun approach that allows analysis of different samples
simultaneously and offers evaluation of changes in protein
composition in an unbiased and comprehensive manner. After
lysis, phagosomal proteins were precipitated, digested, and
labeled (Figure S4A). Phagosomal proteins of resting cells were
labeled with light propionate (12C3), whereas proteins of LPS-
treated cells were labeled with heavy propionate (13C3). Since
equal amounts of both samples were mixed prior to liquid chro-
matography-tandem mass spectrometry (LC-MS/MS) analysis,
the mass difference of labeled peptides further allowed a quan-
titative enrichment analysis (Figure S4B).
The identified phagosomal proteins found in two independent
datasets were analyzed according to their functional categories.
Proteins of lysosomal origin (V type proton ATPase, hydrolases),
and proteins involved in vesicular trafficking and proteasomal
degradation, as well as ER-associated proteins, are shown in
Table 1. The majority of lysosomal hydrolases, including
LAMP-1, LAMP-2, cathepsin B and D, and subunits of the
V-type proton ATPase complex, were all enriched in phago-
somes of resting BMDCs. Most proteins involved in fusion and
vesicular trafficking, including syntaxins, Vps proteins, and Rab
GTPases, as well as ER- and proteasome-related proteins,
were found in similar proportions in resting and LPS-treated
BMDC phagosomes.
We confirmed some of the LC-MS/MS results using Western
blotting by comparing amounts of LAMP-1 and cathepsin D after
loading equal amounts of protein (Figure S4C). Rab7 and
gp91phox (a membrane subunit of the NADPH oxidase com-
plex), were found in similar amounts in phagosomes from resting
and activated BMDCs (Figure S4C). Phagosome lysates were
devoid of Ykt6, a SNARE molecule involved in retrograde trans-
port from Golgi to the ER that has been shown previously to be
absent in purified DC phagosomes (Cebrian et al., 2011), con-
firming purity of the phagosome preparations in this study.
IRAP (an antigen-trimming peptidase), as well as the anti-
gen peptide transporter TAP2, were found in phagosomes
from both resting and LPS-treated BMDCs, whereas the MHC
I molecule H-2Kb was clearly enriched in phagosomes fromc.
LPS-treated DCs (Figure S4D). Other MHC I molecules, tapasin
and, less notably, MHC II molecules, were also enriched in phag-
osomes from LPS-treated DCs, but the number of identified
unique peptides was low. Altogether, these results show that
phagosomes from resting BMDCs are enriched in proteins of
lysosomal origin, as compared to phagosomes from LPS-
treated DCs, indicating that LPS induces a reduction in fusion
between phagosomes and lysosomes.
LPS Induces Perinuclear Clustering of Lysosomes in
Maturing DCs
To better understand at the single cell level the observed reduc-
tion in phago-lysosome fusion, we used confocal immunofluo-
rescence and cryo-immunoelectron microscopy. In resting
BMDCs, LAMP-1 positive organelles showed a wide peripheral
distribution (Figure 3A, upper panel). In contrast, the majority
of LPS-treated BMDCs exhibited peri-nuclear clustering of
LAMP-1-positive compartments and were devoid of these or-
ganelles in the cell periphery (Figure 3A, lower panel). The major-
ity of phagocytosed bbOVA in resting cells was positive for
LAMP-1 (Figure 3B, upper panel; Figures 3C and 3E), while
most phagosomes in LPS-treated cells were not (Figure 3B,
lower panel; Figures 3D and 3E). We observed a clear correlation
in LPS-treated BMDCs between the peri-nuclear clustering of
LAMP-1-positive compartments and phagosomes devoid of
LAMP-1.
To investigate the mechanism involved, we next visualized
fusion between fluorescent lysosomes and phagosomes using
time-lapse video microscopy and LifeAct-GFP-expressing
BMDC cultures. We analyzed the duration between uptake
(formed phagosomes were positive for GFP-actin) until they ac-
quired fluorescent WGA that was pre-loaded into lysosomes. All
phagosomes in resting BMDCs rapidly acquired lysosomal WGA
(Figure 4A and Movie S1), while BMDCs treated with LPS were
heterogeneous in terms of phago-lysosome fusion. Certain cells
displayed rapid fusion between lysosomes and phagosomes,
which was comparable to resting cells. In others, fusion between
phagosomes and lysosomes was hardly visible (Figure 4B).
Those LPS-treated cells that showed reduced fusion also dis-
played peri-nuclear clustering of lysosomes (Figures 3A and
3B). To quantify these results, we first measured the time be-
tween phagosome formation (accumulation of fluorescent
F-actin around the beads) and fusion with lysosomes (fluores-
cent WGA around the beads). In both resting and LPS-treated
DCs, when it occurred, fusion with lysosomes took place on
average 20 min after uptake (Figure 4C, black symbols). In
LPS-treated BMDCs, however, we found an additional popula-
tion of cells in which phagosomes did not fuse with lysosomes,
even 180 min after uptake (Figure 4C, red symbols). This popu-
lation of BMDCs almost exclusively displayed peri-nuclear clus-
tering of lysosomes (Figure 4D). The results were quantified
measuring the relative area covered by lysosomal compartments
using a quantitative and automated Fiji macro. Values between
0.5 and 0.8 are characteristic of a wide peripheral distribution
of lysosomes (a value of 1 means the total cell area is occupied
by these organelles). In contrast, values between 0.1 and
0.4 correspond to lysosome clustering. LPS-treated BMDCs
showed significantly lower values than resting BMDCs indicating
lysosome clustering (Figure 4E). Therefore, as suggested by ourImmprevious observations, lysosomes are organized in tight perinu-
clear clusters only in LPS-treated BMDCs that fail to fuse phag-
osomes with lysosomes.
To investigate a possible mechanism accounting for the
reduced phago-lysosome fusion, we tracked single phagocy-
tosed beads over long distances to analyze phagosomalmotility,
reflecting migration along cytoskeleton elements—most pre-
sumably along microtubules (Blocker et al., 1997). The results
consistently showed that LAMP-1 recruitment to phagosomes
was abolished in LPS-treated BMDCs bearing clustered lyso-
somes. On the contrary, in BMDCs displaying dispersed lyso-
somes, from either resting or LPS-treated conditions, LAMP-1
was rapidly and efficiently recruited to phagosomes with the
same kinetics (Figure 4F). We found that in resting BMDCs,
phagosomes migrated with a mean velocity of 0.88 ± 0.11 mm/
min before fusion with lysosomes. Migration decreased signifi-
cantly after fusion with lysosomes (to 0.47 ± 0.02 mm/min),
both in resting and non-clustered LPS-treated BMDCs (Fig-
ure 4G). Displacement of phagosomes was strongly reduced
(0.26 ± 0.02 mm/min) in LPS-treated BMDCs with clustered lyso-
somes (Figure 4F). These results establish a strong correlation
between the distribution of lysosomes and their fusion with
phagosomes. Together with the observation that phagosomes
move very slowly in these cells, the results suggest that the
lack of phago-lysosome fusion in maturing BMDCs could be
due to the sequestration of lysosomes in a part of the cell that
phagosomes cannot reach effectively.
Inhibition of Phago-Lysosome Fusion Is Specific to TLR
Ligand-Mediated Stimulation
To investigate whether other stimuli that induce DC maturation
also impair phago-lysosomal fusion and promote lysosome re-
distribution, we treated BMDCs with the TLR7 ligand R848 or
the TLR9 ligand CpG for 16 hr. Both induced increased expres-
sion of activation markers, similar to LPS (Figure S5A). Phagoso-
mal degradation of bbOVA was also delayed as compared to
resting cells, but to a lower extent than in LPS-treated DCs (Fig-
ure S5B). R848 and CpG induced lysosomal accumulation in the
peri-nuclear area (Figure S5C), which was also less pronounced
than in LPS-treated BMDCs (Figure S5D). In contrast, treatment
of DCs with TNF, a pro-inflammatory cytokine that also induced
effective increased expression of activation markers (Fig-
ure S5E), did not have any impact on phagosomal antigen degra-
dation (Figure S5F) or lysosomal clustering (Figure S5G). We also
tested whether LPS induces similar effects in bone-marrow-
derived macrophages. While a faint reduction in OVA degrada-
tion was detected, no clustering of lysosomes was evident after
16 hr of LPS treatment (data not shown). Therefore, reduced
phago-lysosome fusion and lysosomal clustering are induced
only by TLR engagement (and not by other DC activation agents)
and selectively in DCs (and not in macrophages).
Rab34 Controls Peri-Nuclear Accumulation of
Lysosomes, Delays Phagosome Maturation, and
Induces Efficient Cross-Presentation
To gain further insight on themolecular mechanisms responsible
for the reduction in phago-lysosome fusion in maturing DCs, we
next examined the possible role of the GTPase Rab34. In macro-
phages, Rab34 is involved in the positioning of lysosomes in theunity 43, 1087–1100, December 15, 2015 ª2015 Elsevier Inc. 1091
Table 1. Phagosomes of Resting DCs Are Enriched in Phago-lysosomal Fusion Markers
UniProt / SwissProt
Accession Gene Name Protein Name
Fold Change
(repl. 1)
Fold Change
(repl. 2)
Peptides in Both
Replicates
V-type proton ATPase complex
Q9R1Q9 Atp6ap1 V-type proton ATPase subunit S1 2.27 2.33 2, 2
P51863 Atp6v0d1 V-type proton ATPase subunit d 1 2.21 2.15 4, 4
P50516 Atp6v1a V-type proton ATPase catalytic subunit A 2.32 3.10 2, 4
P62814 Atp6v1b2 V-type proton ATPase subunit B 2.33 2.63 4, 7
Q9Z1G3 Atp6v1c1 V-type proton ATPase subunit C 1 2.66 2.81 7, 10
P50518 Atp6v1e1 V-type proton ATPase subunit E 1 2.44 2.64 4, 5
Q9D1K2 Atp6v1f V-type proton ATPase subunit F 2.51 2.43 3, 3
Q9CR51 Atp6v1g1 V-type proton ATPase subunit G 1 2.02 2.63 2, 2
Q8BVE3 Atp6v1h V-type proton ATPase subunit H 2.35 3.00 3, 4
Lysosomal and plasma membrane hydrolases
P97449 Anpep Aminopeptidase N 1.55 1.06 3, 2
P50429 Arsb Arylsulfatase B 3.00 2.96 1, 2
Q9WV54 Asah1 Acid ceramidase 2.95 2.38 1, 5
P41731 Cd63 CD63 antigen 3.12 2.48 2, 2
P10605 Ctsb Cathepsin B 2.46 4.88 2, 2
P18242 Ctsd Cathepsin D 3.52 3.89 6, 8
P56542 Dnase2 Deoxyribonuclease-2-alpha 3.70 6.13 3, 2
Q9Z0L8 Ggh Gamma-glutamyl hydrolase 2.02 3.10 2, 3
P51569 Gla Alpha-galactosidase A 3.91 4.19 2, 1
Q60648 Gm2a Ganglioside GM2 activator 1.97 7.24 2, 2
P12265 Gusb Beta-glucuronidase 2.33 5.36 6, 4
P29416 Hexa Beta-hexosaminidase subunit alpha 2.26 2.24 2, 1
P20060 Hexb Beta-hexosaminidase subunit beta 2.55 1.75 3, 1
P11438 Lamp1 Lysosome-associated membrane glycoprotein 1 2.87 2.52 3, 3
P17047 Lamp2 Lysosome-associated membrane glycoprotein 2 2.41 1.83 3, 3
Q9Z0M5 Lipa Lysosomal acid lipase hydrolase 2.75 3.09 2, 3
O09159 Man2b1 Lysosomal alpha-mannosidase 3.39 3.82 2, 1
Q7TMR0 Prcp Lysosomal Pro-X carboxypeptidase 2.12 6.98 2, 2
Q61207 Psap Sulfated glycoprotein 1 3.09 4.12 4, 5
Q920A5 Scpep1 Retinoid-inducible serine carboxypeptidase 1.53 5.25 2, 2
P58242 Smpdl3b Acid sphingomyelinase-like phosphodiesterase 3b 2.07 1.18 2, 2
Q9JJF9 Sppl2a Signal peptide peptidase-like 2A 1.38 1.36 1, 2
Fusion and vesicular trafficking
O35643 Ap1b1 AP-1 complex subunit beta-1 1.25 1.25 3, 1
Q9Z1T1 Ap3b1 AP-3 complex subunit beta-1 1.27 1.50 2, 1
Q9D8B3 Chmp4b Charged multivesicular body protein 4b 1.26 1.45 4, 2
O08917 Flot1 Flotillin-1 1.84 2.34 4, 7
Q60634 Flot2 Flotillin-2 1.74 2.75 2, 5
Q61598 Gdi2 Rab GDP dissociation inhibitor beta 1.12 1.72 3, 5
P62821 Rab1a Ras-related protein Rab-1A 1.15 1.22 3, 4
Q9D1G1 Rab1b Ras-related protein Rab-1B 1.09 1.20 5, 7
P53994 Rab2a Ras-related protein Rab-2A 1.14 1.44 2, 3
P35278 Rab5c Ras-related protein Rab-5C 1.24 1.74 1, 5
P35279 Rab6a Ras-related protein Rab-6A 1.07 1.02 1, 3
P51150 Rab7a Ras-related protein Rab-7A 1.22 1.74 5, 7
P61028 Rab8b Ras-related protein Rab-8B 1.34 1.37 2, 1
Q9R0M6 Rab9a Ras-related protein Rab-9A 1.30 1.95 1, 2
(Continued on next page)
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Table 1. Continued
UniProt / SwissProt
Accession Gene Name Protein Name
Fold Change
(repl. 1)
Fold Change
(repl. 2)
Peptides in Both
Replicates
P46638 Rab11b Ras-related protein Rab-11B 1.15 1.23 2, 1
Q91V41 Rab14 Ras-related protein Rab-14 1.13 1.66 3, 4
P35293 Rab18 Ras-related protein Rab-18 1.00 1.32 2, 2
Q9ERI2 Rab27a Ras-related protein Rab-27A 1.15 1.08 2, 2
O09044 Snap23 Synaptosomal-associated protein 23 1.10 1.41 2, 2
O70492 Snx3 Sorting nexin-3 1.19 1.79 1, 3
Q9D8U8 Snx5 Sorting nexin-5 1.20 1.24 1, 2
Q64704 Stx3 Syntaxin-3 1.17 1.48 2, 3
O70439 Stx7 Syntaxin-7 1.63 1.30 2, 2
Q9QZ88 Vps29 Vacuolar protein sorting-associated protein 29 1.45 2.01 2, 2
Q9EQH3 Vps35 Vacuolar protein sorting-associated protein 35 1.31 1.70 3, 3
P46467 Vps4b Vacuolar protein sorting-associated protein 4B 1.76 1.09 4, 3
O88384 Vti1b Vesicle transport through interaction with t-SNAREs 1B 1.15 1.86 1, 2
Proteasomal degradation
Q9R1P4 Psma1 Proteasome subunit alpha type-1 1.02 1.43 2, 1
Q9R1P0 Psma4 Proteasome subunit alpha type-4 1.04 1.40 3, 2
Q9Z2U1 Psma5 Proteasome subunit alpha type-5 1.02 1.41 2, 2
Q9Z2U0 Psma7 Proteasome subunit alpha type-7 1.09 1.01 4, 1
P46471 Psmc2 26S protease regulatory subunit 7 1.32 3.07 2, 1
P97371 Psme1 Proteasome activator complex subunit 1 1.44 1.16 3, 3
ER-associated proteins
O55143 Atp2a2 SR/ER calcium ATPase 2 1.15 1.13 7, 3
Q64518 Atp2a3 SR/ER calcium ATPase 3 1.21 1.34 3, 2
P14211 Calr Calreticulin 1.11 1.23 6, 9
P35564 Canx Calnexin 1.17 1.40 6, 13
P57759 Erp29 ER resident protein 29 1.01 1.19 4, 6
Q9D1Q6 Erp44 ER resident protein 44 1.00 1.06 1, 3
P07901 Hsp90aa1 Heat shock protein HSP 90-alpha 1.27 1.01 4, 6
P11499 Hsp90ab1 Heat shock protein HSP 90-beta 1.40 1.13 2, 3
Q61316 Hspa4 Heat shock 70 kDa protein 4 1.10 1.41 6, 2
P20029 Hspa5 78 kDa glucose-regulated protein 1.13 1.29 9, 15
P63017 Hspa8 Heat shock cognate 71 kDa protein 1.06 1.22 9, 10
P09103 P4hb (Pdia1) Protein disulfide-isomerase 1.08 1.09 10, 13
P27773 Pdia3 Protein disulfide-isomerase A3 1.09 1.25 9, 8
P08003 Pdia4 Protein disulfide-isomerase A4 1.03 1.10 13, 15
Q922R8 Pdia6 Protein disulfide-isomerase A6 1.10 1.17 4, 4
Q01853 Vcp Transitional endoplasmic reticulum ATPase 1.24 1.03 4, 3
Phagosomes containing bbOVAwere isolated from resting and LPS-treated BMDCs after 30 min pulse and 60min chase. After lysis and precipitation,
samples were labeled with 12C3- (resting cells) and
13C3-propionate (LPS-treated cells), equal amounts were mixed and analyzed by LC-MS/MS.
Shown are functional categories of proteins that were identified in two independent experiments (repl. 1 and 2) including their fold change. Values
above 2.02 (repl. 1) and 2.67 (repl. 2) represent enrichment in phagosomes of resting DCs, while values below 1.52 (repl. 1) and 1.63 (repl. 2)
show enrichment in phagosomes of LPS-treated DCs. See also Figure S4.peri-nuclear region (Wang and Hong, 2002). Rab34 also has a
role in the transport of lysosomal cargo to phagosomes (Kasma-
pour et al., 2012) and was proposed to play a role in cross-pre-
sentation, based on siRNA screening (Zou et al., 2009). We used
siRNA-mediated gene silencing to decrease expression of
Rab34. Transfection did not alter the phenotype of BMDCs,
which responded normally to LPS (Figures S6A and S6B).
Rab34 expression was analyzed by Western blotting (FiguresImm5A and S6C). Four different siRNA inhibited Rab34 expression
with varying efficiencies as compared to the control (Figure S6C).
siRNA #4 was the most efficient at silencing Rab34. Silenced
Rab34 did not affect the kinetics of phago-lysosome fusion in
resting BMDCs (Figures 5B and 5C). In contrast, in Rab34
silenced BMDCs we failed to observe any LPS-induced delay
in OVA degradation or phago-lysosome fusion (Figures 5B and
5C). This effect was confirmed using Rab34 siRNA #1, whichunity 43, 1087–1100, December 15, 2015 ª2015 Elsevier Inc. 1093
Figure 3. Lysosomal Compartments of LPS-
Treated DCs Display Peri-nuclear Clustering
BMDCs were grown in absence (resting) or pres-
ence of 100 ng/ml LPS (LPS-treated), labeled, and
analyzed by confocal microscopy.
(A) Shown are projections of stainings of LAMP-1
(green), F-actin (gray), and DNA (blue).
(B) The same cells were allowed to internalize
bbOVA for 30 min followed by a chase period of
60min. In merged images, LAMP-1 (green), F-actin
(gray), DNA (blue), and bbOVA (red) are shown.
Insets display phagosomes of both cell types.
(C and D) Electron microscopy of resting (C) and
LPS-treated BMDCs (D) after labeling of LAMP-1
with 10 nm gold.
(E) Quantification of gold particles per phagosome
area after 0 min and 60 min phagosome matura-
tion. At least 60 phagosomes from three indepen-
dent experiments for each condition were
measured. Error bars represent SD. Scale bars
represent 10 mm (A and B) and 1 mm (C and D),
respectively.has a partial effect on both Rab34 silencing and the reversion
of the LPS-induced reduction in phago-lysosome fusion (Figures
S6D and S6E). These results show that Rab34 expression is
dispensable for phago-lysosome fusion in resting BMDCs but
is required for the reduction of phago-lysosome fusion induced
by LPS.
Because of the correlation between lysosome clustering
and fusion with phagosomes, we analyzed the effect of Rab34
silencing on lysosome distribution in resting and LPS-treated
BMDCs (Figures 6A and 6B). Silenced Rab34 did not affect the
disperse distribution of lysosomes in resting BMDCs (Figure 6A).1094 Immunity 43, 1087–1100, December 15, 2015 ª2015 Elsevier Inc.In contrast, Rab34 silencing prevented
the induction of lysosome clustering by
LPS (Figure 6B). Single cell analysis was
performed to quantify the subcellular
distribution of lysosomes in control and
Rab34 silenced BMDCs, as described
above. While resting cells transfected
with control siRNA had a lysosomal rela-
tive area between 0.5 and 0.8 (character-
istic for a wide peripheral distribution of
lysosomes) in approximately 35%–40%
of LPS-treated control cells the lysosomal
relative area value was reduced to 0.1–0.4
(corresponding to the clustering of lyso-
somes; Figure 6C). These results show
that Rab34 silenced BMDCs lose their
ability to cluster lysosomes after activa-
tion with LPS.
Finally, we tested whether silencing
of Rab34 also prevents the increase in
cross-presentation efficiency induced by
LPS. The processed SIINFEKL peptide
was used as a control for cross-presenta-
tion, which did not exhibit differences
between the different samples. In cells
transfected with control siRNA, LPS treat-ment increased the efficiency of cross-presentation for both
bbOVA and sOVA (Figure 6D). In contrast, in Rab34 silenced
BMDCs LPS failed to induce any significant increase in the effi-
ciency of OVA cross-presentation (Figure 6E). Therefore, expres-
sion of Rab34 is required for the increase in the efficiency of
cross-presentation observed after 16 hr of LPS stimulation.
DISCUSSION
Lysosome clustering during DC maturation was observed over
15 years ago (Pierre et al., 1997), but its functional relevance
Figure 4. DCs with Peri-nuclear Clustering of Lysosomes Are Strongly Reduced in Phago-lysosomal Fusion
BMDCs expressing LifeAct-GFP (green) were pre-incubated with fluorescently-labeled WGA that accumulates in lysosomes (red). After lysosomal loading,
bbOVA was added and phagocytic uptake (green arrows) and phago-lysosomal (P-L) fusion (red arrow) were analyzed by video microscopy in resting (A) and
LPS-treatedBMDCs (B). P-L fusion kinetics were quantified in both cell types (C) aswell as percentages of DCswith peripheral distribution of lysosomes (black) or
peri-nuclear clustering of lysosomes (red) 180 min after addition of beads (D). Additionally, DCs were also sub-divided in cells that contained fused (F) and non-
fused (non-F) phagosomes. Clustering of lysosomes in non-treated and LPS-treated BMDCs was measured; intracellular areas of DCs were quantified for their
relative LAMP-1+ areas (cell number > 30 for each analyzed condition) (E). Recruitment of LAMP-1 to phagosomes was evaluated by tracking each phagosome
individually; average of all phagosomes for each condition is graphed (periph.: peripheral distribution of lysosomes; clust.: lysosomes clustered in the peri-nuclear
region) (F). Migration speed of phagosomes along microtubules was quantified; b.f. = before fusion of phagosomes and lysosomes, a.f. = after fusion (G).
Shown is a representative example of two independent experiments. Error bars represent SD. Scale bars represent 10 mm. See also Movies S1 and S2 and
Figures S3 and S5.was unknown until the present study. Our findings suggest that
perinuclear clustering of lysosomes in maturing DCs, together
with reduced displacements of phagosomes along microtu-Immbules, prevent effective phago-lysosome fusion, thereby pro-
moting antigen cross-presentation. This conclusion is based
on the following observations. First, within a heterogeneousunity 43, 1087–1100, December 15, 2015 ª2015 Elsevier Inc. 1095
Figure 5. Silencing of Rab34 Reverts Delayed Phagosome Matura-
tion in LPS-Treated DCs
BMDCs were transfected with scramble siRNA (control) and Rab34 siRNA #4
(Rab34 silenced). Efficiency of silencing was tested and quantified by Western
blotting (A). BMDCs were incubated for 16 hr in presence or absence of
100 ng/ml LPS before bbOVAwas phagocytosed. Phagosomal degradation of
OVA (B) as well as phagosomal acquisition of LAMP-1 (C) were analyzed after
different chase periods by flow organellocytometry. Shown are representative
data of three independent experiments. Error bars represent SD. See also
Figure S6.population of maturing DCs, including cells bearing non-clus-
tered and clustered lysosomes, there was a strict negative cor-
relation between lysosomal clustering and phago-lysosome
fusion. Second, silencing of Rab34 prevented both lysosomal
clustering and the inhibition of phago-lysosome fusion induced
by LPS, without affecting phagosomal maturation or lysosomal1096 Immunity 43, 1087–1100, December 15, 2015 ª2015 Elsevier Indistribution in resting BMDCs. Finally, the observation that
silencing of Rab34 also prevented the increased efficiency of
cross-presentation induced by LPS, but does not affect cross-
presentation in untreated BMDCs, indicates that reducing the
fusion of phagosomes and lysosomes plays a critical role in
the increased efficiency of cross-presentation by maturing
DCs. Together, these results suggest that DCs have developed
a dedicated mode of control of phago-lysosomal fusion, based
on a Rab34-dependent re-organization of the intracellular distri-
bution of lysosomes, that transiently promotes the efficiency of
cross-presentation in maturing DCs.
The innate response of DCs to pathogens includes a series of
developmentally controlled changes of cellular morphology and
function. Many of these changes relate to antigen presentation
and T cell activation (Reis e Sousa, 2006). The inhibition of
phago-lysosome fusion reported here starts only around 12 hr
after TLR4 engagement. It is assumed, however, that in most
cases antigen and TLR ligands are encountered and phagocy-
tosed simultaneously. What is the physiological relevance of
the process that we are reporting here? There are several
possible answers to this question. First, although a single bac-
terium might bear sufficient LPS to activate a DC, it might not
contain sufficient antigen to induce effective priming. Our re-
sults predict that activated DCs enter a ‘‘surveillance’’ state
that allows uptake of additional microbes (as the infection de-
velops and more microbes become available) and efficient
cross-presentation for up to 16–18 hr after TLR engagement,
even if the precise kinetics of this transient phase can change
depending on the concentration and purity of the LPS prepara-
tions and the type of DCs analyzed. It is also possible that in the
course of infections, pathogens or infected cells produce solu-
ble TLR ligands that ‘‘prime’’ DCs locally several hours before
the actual microbe is encountered and taken up. Finally, the
idea of a TLR ligand-induced phase of increased cross-presen-
tation is consistent with the notion that DCs need to take up and
cross-present antigens while pathogens are present, but before
tissue destruction becomes too important, thus avoiding the up-
take of self-antigens and their cross-presentation, which could
represent a potential danger due to self-reactivity.
A recent study from the Villadangos group has shown that DCs
activated in vivo by CpG for 12 hr fail to cross-present antigen
from dead cells, while ‘‘indirectly’’ activated DCs (i.e., TLR-defi-
cient DCs activated by secreted cytokines in a wild-type context)
could take up and cross-present antigen after activation (Vega-
Ramos et al., 2014). Consistent with these results, 16 hr after in-
jection of LPS, DCs failed to take up dead cells or cross-present
antigen from dead cell-OVA in vivo (data not shown). These re-
sults indicate that the mechanism reported here is not relevant
for antigens expressed in dying non-infected cells, consistent
with the idea that early after activation DCs focus their uptake
and antigen presentation capacity on non-self antigen sources.
In our in vitro experiments, TNF, an inflammatory cytokine that
effectively activates DCs and is produced by different phago-
cytes in response to TLR engagement, did not induce a
phago-lysosome block or lysosomal clustering. Although ‘‘indi-
rectly’’ activated DCs do not present antigen to CD4+ T cells
(Spo¨rri and Reis e Sousa, 2005), it is still unclear whether they
are competent for cross-presentation (Kratky et al., 2011;
Vega-Ramos et al., 2014). Depending on the experimentalc.
Figure 6. Silencing of Rab34 Reduces Effi-
cient Cross-Presentation in LPS-Treated
DCs
BMDCs transfected with scramble siRNA (control)
and Rab34 siRNA #4 (Rab34 silenced) were
labeled and analyzed by confocal microscopy.
Shown are projections of stainings of LAMP-1
(green) and F-actin (gray) of control (A) and Rab34
silenced BMDCs (B) before and after LPS treat-
ment. Intracellular areas of DCs were quantified for
their relative LAMP-1+ areas (cell number > 80 for
each analyzed condition) (C). The same cells were
also analyzed for cross-presentation of bbOVA (left
panel), sOVA (middle panel), and SIINFEKL pep-
tide (right panel) measured by CD69 expression of
OT-I T cells co-cultured with control (D) and Rab34
silenced BMDCs (E) in presence and absence of
LPS. Shown are normalized data of three inde-
pendent experiments. Scale bars represent 10 mm.
See also Figure S6.systems (including kinetics, amounts of antigen and nature of
TLR ligands), the block in phago-lysosome fusion described
herein may or may not operate. It is also possible, however,
that ‘‘indirectly’’ in vivo activated DCs receive a combination of
innate signals, in addition to TNF, that induce lysosomal clus-
tering and inhibit phago-lysosome fusion in vivo. Finally, the phe-
nomenon that we describe here could also be relevant to DCs inImmunity 43, 1087–1100, Demucosae, which are constantly stimu-
lated by TLR ligands from microbiota or
to infection-related autoimmunity, during
which TLR engagement could promote
the cross-presentation of self-antigens.
Although it was unexpected that
maturing DCs failed to fuse phagosomes
to lysosomes, it is not unexpected that
such a block results in enhanced cross-
presentation in DCs. Abundant previous
evidence by others and us, suggest
that decreased phagosome cargo
degradation favors cross-presentation
(Graham et al., 2007; Jancic et al.,
2007; Mantegazza et al., 2008; Savina
et al., 2006, 2009). Slow degradation
probably spares MHC I-restricted epi-
topes in the endocytic pathway, and al-
lows effective export to the cytosol of
large protein fragments that can be pro-
cessed by the proteasome. Of note, the
increased efficacy of cross-presentation
reported here occurs while the efficiency
of phagocytosis is progressively
reduced, suggesting that maturing DCs,
even if they cross-present antigens
more efficiently, take up less antigen by
phagocytosis, which most likely partici-
pates to reducing antigen presentation
by MHC II during this transient phase.
Slow internalization has indeed previ-ously been shown to favor cross-presentation in human DCs,
after targeting of antigens to relatively inefficient endocytic re-
ceptors, such as CD40 (Hoffmann et al., 2001).
Although the present study identifies a mechanism that is
turned on several hours after DC activation by TLR engagement,
upregulation of cross-presentation starts as soon as a TLR
ligand-bearing particle is taken up. We and others have showncember 15, 2015 ª2015 Elsevier Inc. 1097
previously that when DCs encounter antigen and TLR ligands
simultaneously, cross-presentation is increased (Nair-Gupta
et al., 2014). The mechanisms involved in this early (first few
hours) increase in cross-presentation have been investigated in
many studies: Increased recruitment of MHC I to phagosomes
(Nair-Gupta et al., 2014), decreased recruitment of lysosomal
enzymes (Delamarre et al., 2005), and higher pH (Savina et al.,
2006) have all been proposed to participate to increased
cross-presentation in the first few hours after antigen uptake.
It has also been reported that during late phases of DC matu-
ration in response to LPS and other TLR ligands that cross-pre-
sentation is down-modulated (Gil-Torregrosa et al., 2004;
Wagner and Cresswell, 2012; Samie and Cresswell, 2015).
Our earlier study showed that after 24–30 hr of LPS stimulation
DCs fail to cross-present antigen, probably due to reduced an-
tigen export to the cytosol (Gil-Torregrosa et al., 2004). More
recently, Cresswell and colleagues showed that down-modula-
tion of cross-presentation is induced by peptidoglycan contam-
inating some LPS preparations and also by high doses of pure
LPS (Wagner and Cresswell, 2012). They also showed that
TFEB coordinates the selective down-modulation of antigen
cross-presentation at these late times (24 hr) after LPS-medi-
ated stimulation by promoting endosomal acidification and an-
tigen degradation (Samie and Cresswell, 2015). These studies,
however, did not investigate the transient phase of induction of
cross-presentation, but since TFEB promotes phagosomal
acidification during late phases of DC maturation, it is probably
not involved in the transient increase of cross-presentation
analyzed here.
We propose that the Rab34-dependent block in phago-
lysosome fusion is a mechanism for this intermediate phase
of prolonged enhancement of antigen cross-presentation. The
generation of conditional Rab34/ mice will allow addressing
the exact role of increased antigen cross-presentation by TLR
ligand engagement for CD8+ T cell responses to pathogens
and tumors. Our findings, nevertheless, should help designing
more effective CD8+ T cell vaccination strategies.
EXPERIMENTAL PROCEDURES
Cell Generation
C57BL/6 female mice and C57BL/6 TCR (Va2, Vb5) transgenic mice (OT-I)
were obtained from Charles River Laboratories, Janvier, and CDTA. All animal
procedures were in accordance with the guidelines and regulations of the
French Veterinary Department or were approved by the animal ethical commit-
tee of Ghent University, Belgium. BMDCs and splenic DCs were generated
by culture in GM-CSF-containing medium. In vitro maturation of cells was
induced by a 16 hr treatment with 100 ng/ml of ultrapure LPS from E. coli
0111:B4 (Invivogen) unless otherwise stated. For full information onmice, cells
and antibodies, see Supplemental Experimental Procedures.
Bead Preparation
Amine-modified polystyrene beads (Polysciences) were pre-activated with
8% (vol/vol) glutaraldehyde for 4 hr at room temperature.Beadswereconjugated
to low endo ovalbumin (Worthington Biochemicals) and Alexa Fluor N-hydroxy-
succinimide ester dyes (Life Technologies) on a rotating wheel overnight at 4C
at concentrations of 0.5 mg/ml and 0.1 mg/ml, respectively. After quenching in
PBS containing 0.5 M glycine for 30 min, beads were used for phagocytosis
assays.
As for the in vivo cross-presentation experiments, polybeads (Polysciences)
were coated with 20 mg/ml soluble OVA overnight and washed three times
with PBS before injection.1098 Immunity 43, 1087–1100, December 15, 2015 ª2015 Elsevier InFlow Organellocytometry
The flow cytometry techniques used to analyze the capacity of phagosomes
to degrade proteins and acquire LAMP-1 have been described previously
(Savina et al., 2010). In brief, after phagocytic uptake of bead-bound OVA, cells
were washed in cold PBS and non-specific binding sites were blocked by
incubation with CD16/32 antibody (BD Biosciences). Subsequently, in all sam-
ples, external beads were labeled and excluded from analysis. Samples were
resuspended in homogenization buffer and disrupted mechanically with 2 ml
syringes and 22-gauge needles (Terumo Medical). After centrifugation, the
post-nuclear supernatant was transferred to 96-well conical microplates
followed by labeling on ice using antibodies against OVA, LAMP-1, and
LAMP-2. Samples were measured by flow cytometry using the LSR II cytom-
eter (BD Biosciences) and analyzed by FlowJo software (TreeStar).
In Vitro Cross-Presentation Assays
BMDCs were incubated with bbOVA, with sOVA, or with different concentra-
tions of the SIINFEKL peptide. After 1 hr, DCs were washed and co-cultured
with purifiedCFSE-OT-I CD8+ T cells for 3 days. To evaluate T cell proliferation,
diminution of CFSE staining on the TCR+ CD8+ population was measured by
flow cytometry. Alternatively, cells were incubated for 5 hr with the same
antigens. Then, cells were fixed with 0.008% glutaraldehyde in PBS. Cross-
presentation was analyzed either by co-culturing with B3Z cells for 16 hr (de-
tecting b-galactosidase activity by optical density at 590 nm using CPRG as
substrate) or by co-culturing with OT-I CD8+ T cells (activation was measured
after 16 hr by expression of CD69).
In Vivo Maturation of DCs and Cross-Presentation Assays
A dose of 10 mg LPS (ultrapure, E. coli 0111:B4, Invivogen) was chosen to
generate maximum numbers of activated DCs judged by upregulation of co-
stimulatory molecules (CD40, CD86), but the lowest associated pathology.
Endotoxin-free PBS was used for control injections. For bbOVA, LPS was in-
jected intraperitoneally 14 hr prior to experiments, followed by intravenous
injection of beads and 2 hr of phagocytosis. Subsequently, spleens were har-
vested and DCs were purified by CD11c negative selection (Miltenyi) followed
by sorting CD8+ bead+ DCs. For sOVA and OVA-IC, LPS was injected 15.5 hr
prior to experiments, and the antigen was administered i.v. for 30 min. Again,
spleens were collected, followed by two rounds of CD11c negative selection.
DCs were then co-cultured with OT-I T cells for 16 hr and activation of T cells
was addressed by CD25 and CD69 expression.
siRNA-Mediated Rab34 Gene Silencing
BMDC transfection was performed by electroporation with 4 different siRNA
following the manufacturer’s instructions (Amaxa) with some minor modifica-
tions. Briefly, BMDCs were harvested at day 7 and resuspended in the electro-
poration solution provided with the kit. 2 3 106 cells were distributed per
cuvette and electroporated. Cells were quickly plated back in 6-well plates
with 3 ml of complete medium. After 24 hr, the medium was replaced by fresh
medium. After 48 hr, cells were harvested and analyzed (for sequences and
details, see Supplemental Experimental Procedures).
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, Supplemental Experimental
Procedures, and two movies and can be found with this article online at
http://dx.doi.org/10.1016/j.immuni.2015.11.006.
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